Skip to main content

Month: August 2020

Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)

New data will be presented in an e-poster today at the Virtual Edition of the 46th EBMT Annual MeetingAmsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell-based medicines for the treatment of life-threatening diseases, today announces that new data supporting the Company’s NK cell therapy is being presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). The poster presents data from 13 patients treated with relapsed/refractory acute myeloid leukemia (R/R AML) who received treatment with FC21 expanded NK-cells during a Phase I study conducted by Lucia Mariano da Rocha Silla, MD, PhD, at Hospital de Clínicas de Porto Alegre (HCPA) in Brazil....

Continue reading

Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumabSeven of ten patients discontinued eculizumab and remained on LNP023 as monotherapy, retaining hemoglobin (Hb) levels with no changes in biomarkers of disease activity and with no signs or symptoms of breakthrough hemolysis Phase II results are promising for treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder;1,2 second Phase II study with LNP023 monotherapy in anti-C5 naïve PNH patients ongoing  First-in-class LNP023 – which potently and selectively targets factor B, part of the immune system’s alternative complement pathway3,4,5 – is also in development for several renal conditions with complement system involvement FDA and EMA have granted orphan drug...

Continue reading

VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020

Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPASignificant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides further insight to potential mechanisms of actionVASCEPA is the first and only agent studied on top of statins reported to exhibit coronary plaque regression in hypertriglyceridemic patientsDUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 29, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that the trial results from Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: Final results of the EVAPORATE Trial were presented at ESC Congress 2020, the annual meeting of the European Society of Cardiology, on August 29, 2020, 9:13 am CEST (Central...

Continue reading

Synergy Capital AM: Stocks ended up mixed but S&P 500 kept its pace hitting another fresh new high

Major indices closed down market mixed after concerns about Federal Reserve’s reports on a new framework that could keep interest rates lower for a longer period of time gave investors not much of positivity.Nasdaq fell quite big after tech giants dropped. Amazon is down with 1.2% while Facebook slid 2.3%. Netflix also decreased about 3.9% but Alphabet made a few jump at 1%.Here are the main movements in the Global Stock Market;Stocks– Nasdaq Composite snaps out of its passive pace and fell short losing around 39.72 points or 0.34% to 11,625.34.– S&P 500 hits another fresh new high for the 4th time this week with 5.84 points or 0.17% increased to 3,484.57 as market ends today.– The Dow Jones Industrial Average jumps up with 160.15 or 0.57% change to 28,492.07, deleting some of its loss from yesterday.– The...

Continue reading

Company Announcement 08/2020

August 29, 2020NORDIC SHIPHOLDING A/S Company Announcement: 08/2020H1 Result 2020SummaryThe comparison figures for period ended 30 June 2019 are stated in parenthesis.The very high Time Charter Equivalent (“TCE”) rates arising from the short-term surge in demand for tonnage caused by the COVID-19 pandemic and the oil price war which started in Q1 2020 positively impacted the Group’s earnings in H1 2020.  As a result, the average daily TCE rate earned in H1 2020 by the 5 vessels was approximately 20% and 83% higher than the average TCE rate earned in Q4 2019 and H1 2019, respectively.For the 6 months ended 30 June 2020, the Group generated a profit after tax ofUSD 5.7 million (loss of USD 1.3 million) primarily due to improved TCE revenue generated.Despite the sale of Nordic Ruth in July 2019, TCE revenue rose 59.8% to USD 19.4 million...

Continue reading

Selskabsmeddelelse 08/2020

29. august, 2020NORDIC SHIPHOLDING A/S Selskabsmeddelelse: 08/2020Halvårsrapport – 1. halvår 2020ResuméSammenligningstallene for 1. halvår 2019 er angivet i parentes.De meget højre Time Charter Equivalent (”TCE”) – rater, som resultat af den kortvarige stigning i efterspørgslen efter tonnage forårsaget af COVID-19 pandemien og oliepriskrigen som startede i 1. kvartal 2020, påvirkede koncernens indtjening positivt i 1. halvår 2020. Som følge heraf var den gennemsnitlige daglige TCE-rate, som indtjent af de fem skibe, i første halvår 2020 omkring 20% og 83% højere end den gennemsnitlige TCE-rate indtjent i henholdsvis 4. kvartal 2019 og 1. halvår 2019.For halvåret, der endte den 30. juni 2020, realiserede koncernen et positivt resultat efter skat på USD 5,7 millioner (sammenlignet med et tab efter skat på USD 1,3 millioner) primært...

Continue reading

Taat Lifestyle & Wellness Ltd. Closes First Tranche of Non-brokered Private Placement

LAS VEGAS and VANCOUVER, British Columbia, Aug. 28, 2020 (GLOBE NEWSWIRE) — TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTC: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “Taat”) is pleased to announce that it has closed a first tranche of its previously announced non-brokered private placement of 3,719,005 units (the “Units”) at a price of $0.70 per Unit for gross proceeds of $2,603,303.70 (the “First Tranche”). Each Unit consists of one (1) Share (each, a “Share”) and one-half (1/2) of one (1) transferable Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder thereof to purchase one (1) additional Share of the Company for a period of one year from closing at a price of $1.00 per Share. In the event that the Shares have a closing price on the Canadian Securities Exchange (or such other exchange on which the...

Continue reading

Occidental Announces Early Tender Results in Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes Maturing in 2022 and 2023

HOUSTON, Aug. 28, 2020 (GLOBE NEWSWIRE) — Occidental (NYSE: OXY) today announced the early tender results for the 2022 Notes and 2.70% 2023 Notes (each, as defined below) in connection with its offers to purchase for cash (collectively, the “Tender Offers” and each, a “Tender Offer”) its outstanding 4.10% Senior Notes due 2021 (the “4.10% 2021 Notes”), 2.600% Senior Notes due 2021 (the “2.600% 2021 Notes”), Floating Interest Rate Notes due August 2021 (the “Floating Rate August 2021 Notes” and, together with the 4.10% 2021 Notes and 2.600% 2021 Notes, the “2021 Notes”), Floating Interest Rate Notes due August 2022 (the “Floating Rate August 2022 Notes”), 2.600% Senior Notes due 2022 (the “2.600% 2022 Notes”), 2.700% Senior Notes due 2022 (the “2.700% 2022 Notes”), 3.125% Senior Notes due 2022 (the “3.125% 2022 Notes” and, together...

Continue reading

iSIGN Media Announces Delayed Filing of Required Annual Filings Pursuant to OSC Instrument 51-502

TORONTO, Aug. 28, 2020 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), a leading provider of interactive mobile proximity marketing and public security alert solutions announced in accordance with Ontario Instrument 51-502, Temporary Exemption from Certain Corporate Finance Requirements, of the Ontario Securities Commission (the “Exemption Order”), which was adopted for the purpose of providing certain filing and other relief to issuers in light of the challenges posted by the COVID-19 pandemic, that it will be delaying the filing of certain of its continuous disclosure documents.The Company is relying on the Exemption Order in delaying the filing of its audited annual financial statements and related management’s discussion and analysis and certifications for the fiscal year ended...

Continue reading

The Flowr Corporation Announces Third Tranche of Funding from Terrace Global

TORONTO, Aug. 28, 2020 (GLOBE NEWSWIRE) — The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) is pleased to announce that the Company has closed on a third tranche of funding (the “Third Tranche”) in the amount of C$350,000 pursuant to the Equity Line and Profit Share Agreement (the “Agreement”) with Terrace Global Inc. (TSXV: TRCE) (“Terrace Global”). The Third Tranche will be used to fund the Company’s outdoor medical cannabis site in Aljustrel, Portugal which is jointly operated with Terrace Global (the “Partnership”).“We are very pleased by the progress in Aljustrel and continue to work closely with Terrace Global towards a successful harvest later this year,” commented Vinay Tolia, Chief Executive Officer of Flowr. “Thus far the crops in Aljustrel look very promising and we continue to be on track to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.